Educational project on Minimal Residual Disease (MRD) in multiple myeloma – 2026/2027
This activity is supported by an independent grant from Cloud Pathology Group and by an unrestricted medical contribution from Sanofi. Procedures for further independent support are ongoing.
Minimal Residual Disease (MRD) is emerging as a powerful prognostic marker in multiple myeloma. Advancing knowledge of MRD can support personalised treatment, improve patient outcomes, and facilitate the development of more effective therapeutic strategies.